All Stories

  1. Early Alzheimer´s disease blood biomarkers are associated with a higher risk for postoperative long‐term cognitive decline: Insights from the FINDERI study
  2. Evaluation of fully automated ApoE4 proteotyping for APOE ε4 genotype estimation in the FINDERI cohort
  3. Aggregation-dependent epitope sequence and modification fingerprints of anti-Aβ antibodies
  4. Amyloid Plaques Ameliorate Memory Deficits and Hippocampal Neuron Loss in an Aβ4-42-Driven Alzheimer’s Disease Mouse Model
  5. Characterization of a pathogenic gain-of-function mutation in the N-terminal domain of STAT1 which is reported to be associated with eosinophilic esophagitis
  6. Behavioral assessment and gene expression changes in a mouse model with dysfunctional STAT1 signaling
  7. N-terminal truncation of STAT1 transcription factor causes CD3- and CD20-negative non-Hodgkin lymphoma through upregulation of STAT3-mediated oncogenic functions
  8. Cognitive decline and neuroinflammation in a mouse model of obesity: An accelerating role of ageing
  9. Social inhibition in depressed patients is associated with an altered activation profile of the interleukin-6-inducible transcription factor STAT3
  10. Caffeine and potential use in Alzheimer’s disease
  11. Identification of isoAsp7-Aβ as a major Aβ variant in Alzheimer’s disease, dementia with Lewy bodies and vascular dementia
  12. Apolipoprotein E aggregation in microglia initiates Alzheimer’s disease pathology by seeding β-amyloidosis
  13. Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease model mice
  14. Amino‐terminally elongated Aβ peptides are generated by the secreted metalloprotease ADAMTS4 and deposit in a subset of Alzheimer's disease brains
  15. Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer’s disease
  16. Blood plasma biomarkers for Alzheimer’s disease: Aβ1–42/1–40 vs. AβX–42/X–40
  17. A novel interface between the N-terminal and coiled-coil domain of STAT1 functions in an auto-inhibitory manner
  18. Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease
  19. Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice
  20. Lack of STAT1 co-operative DNA binding protects against adverse cardiac remodelling in acute myocardial infarction
  21. Matrix Development for the Detection of Phosphorylated Amyloid-β Peptides by MALDI-TOF-MS
  22. A Combination of Caffeine Supplementation and Enriched Environment in an Alzheimer’s Disease Mouse Model
  23. Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
  24. Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor
  25. Combined long-term enriched environment and caffeine supplementation improve memory function in C57Bl6 mice
  26. An inhibitory effect on the nuclear accumulation of phospho-STAT1 by its unphosphorylated form
  27. Meprin β knockout reduces brain Aβ levels and rescues learning and memory impairments in the APP/lon mouse model for Alzheimer’s disease
  28. Detection and quantification of Aβ−3–40 (APP669‐711) in cerebrospinal fluid
  29. Long-term caffeine treatment of Alzheimer mouse models ameliorates behavioural deficits and neuron loss and promotes cellular and molecular markers of neurogenesis
  30. Interferon-driven brain phenotype in a mouse model of RNaseT2 deficient leukoencephalopathy
  31. The anti-parallel dimer binding interface in STAT3 transcription factor is required for the inactivation of cytokine-mediated signal transduction
  32. A microRNA signature that correlates with cognition and is a target against cognitive decline
  33. Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau
  34. Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
  35. Physical activity and cognitive stimulation ameliorate learning and motor deficits in a transgenic mouse model of Alzheimer’s disease
  36. Alzheimer’s Disease
  37. Immunotherapy Targeting Amyloid-ß Peptides in Alzheimer’s Disease
  38. Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models
  39. Chronic Memantine Treatment Ameliorates Behavioral Deficits, Neuron Loss, and Impaired Neurogenesis in a Model of Alzheimer’s Disease
  40. Development and Technical Validation of an Immunoassay for the Detection of APP669–711 (Aβ−3–40) in Biological Samples
  41. N‐terminal heterogeneity of parenchymal and vascular amyloid‐β deposits in Alzheimer’s disease
  42. Loss of Hippocampal Calretinin and Parvalbumin Interneurons in the 5XFAD Mouse Model of Alzheimer’s Disease
  43. Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease
  44. N-Terminally Truncated Aß Peptide Variants in Alzheimer’s Disease
  45. N-Terminal Truncated Aβ4-42 Is a Substrate for Neprilysin Degradation in vitro and in vivo
  46. Physical Activity Ameliorates Impaired Hippocampal Neurogenesis in the Tg4-42 Mouse Model of Alzheimer’s Disease
  47. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
  48. The metalloprotease ADAMTS4 generates N-truncated Aβ4–x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer’s disease
  49. Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia
  50. The presubiculum is preserved from neurodegenerative changes in Alzheimer’s disease
  51. Synergistic Effect on Neurodegeneration by N-Truncated Aβ4−42 and Pyroglutamate Aβ3−42 in a Mouse Model of Alzheimer's Disease
  52. N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
  53. Altered neurogenesis in mouse models of Alzheimer disease
  54. Extraction of Soluble and Insoluble Protein Fractions from Mouse Brains and Spinal Cords
  55. Preparation of Crude Synaptosomal Fractions from Mouse Brains and Spinal Cords
  56. Effects of Long-Term Environmental Enrichment on Anxiety, Memory, Hippocampal Plasticity and Overall Brain Gene Expression in C57BL6 Mice
  57. Physical activity delays hippocampal neurodegeneration and rescues memory deficits in an Alzheimer disease mouse model
  58. Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models
  59. The Cannabinoid CB1/CB2 Agonist WIN55212.2 Promotes Oligodendrocyte DifferentiationIn Vitroand Neuroprotection During the Cuprizone-Induced Central Nervous System Demyelination
  60. Endogenous Apolipoprotein E (ApoE) Fragmentation Is Linked to Amyloid Pathology in Transgenic Mouse Models of Alzheimer’s Disease
  61. Alzheimer’s Disease
  62. Immunotherapy Against N-Truncated Amyloid-β Oligomers
  63. Gene Expression Profiling in the APP/PS1KI Mouse Model of Familial Alzheimer’s Disease
  64. N-Truncated Aβ2-X Starting with Position Two in Sporadic Alzheimer’s Disease Cases and Two Alzheimer Mouse Models
  65. Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease
  66. Neprilysin Deficiency Alters the Neuropathological and Behavioral Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease
  67. I716F AβPP Mutation Associates with the Deposition of Oligomeric Pyroglutamate Amyloid-β and α-Synucleinopathy with Lewy Bodies
  68. Immunocytochemical Detection of Intraneuronal Aβ Peptides in Mouse Models of Alzheimer’s Disease
  69. Axonal degeneration in an Alzheimer mouse model is PS1 gene dose dependent and linked to intraneuronal Aβ accumulation
  70. Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease
  71. Deciphering the Molecular Profile of Plaques, Memory Decline and Neuron Loss in Two Mouse Models for Alzheimer’s Disease by Deep Sequencing
  72. Aβ38 in the Brains of Patients with Sporadic and Familial Alzheimer's Disease and Transgenic Mouse Models
  73. Immunolesion-induced loss of cholinergic projection neurones promotes β-amyloidosis and tau hyperphosphorylation in the hippocampus of triple-transgenic mice
  74. Abundance of Aβ5-x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer’s disease
  75. Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease
  76. Oligomeric Pyroglutamate Amyloid-β is Present in Microglia and a Subfraction of Vessels in Patients with Alzheimer's Disease: Implications for Immunotherapy
  77. N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits
  78. Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias
  79. Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer’s disease
  80. N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody
  81. Problems During Aging (Alzheimer’s and Others)
  82. The Arctic AβPP mutation leads to Alzheimer’s disease pathology with highly variable topographic deposition of differentially truncated Aβ
  83. Intraneuronal Aβ accumulation and neurodegeneration: Lessons from transgenic models
  84. Amyloid Precursor Protein Is a Biomarker for Transformed Human Pluripotent Stem Cells
  85. No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease
  86. Antibody 9D5 Recognizes Oligomeric Pyroglutamate Amyloid-β in a Fraction of Amyloid-β Deposits in Alzheimer's Disease without Cross-Reactivity with other Protein Aggregates
  87. AβPP Accumulation and/or Intraneuronal Amyloid-β Accumulation? The 3xTg-AD Mouse Model Revisited
  88. Pyroglutamate Amyloid β (Aβ) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease
  89. Environmental enrichment fails to rescue working memory deficits, neuron loss, and neurogenesis in APP/PS1KI mice
  90. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease
  91. Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease
  92. Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease
  93. Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology?
  94. Overexpression of Glutaminyl Cyclase, the Enzyme Responsible for Pyroglutamate Aβ Formation, Induces Behavioral Deficits, and Glutaminyl Cyclase Knock-out Rescues the Behavioral Phenotype in 5XFAD Mice
  95. Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease
  96. Concomitant detection of β-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice
  97. Intracellular Aβ triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease
  98. Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease
  99. Accumulation of intraneuronal Aβ correlates with ApoE4 genotype
  100. Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients
  101. Histone Deacetylase Inhibitor Valproic Acid Inhibits Cancer Cell Proliferation via Down-regulation of the Alzheimer Amyloid Precursor Protein
  102. Intracellular accumulation of amyloid-beta – a predictor for synaptic dysfunction and neuron loss in Alzheimer’s disease
  103. Neuron Loss in Transgenic Mouse Models of Alzheimer's Disease
  104. Formic acid is essential for immunohistochemical detection of aggregated intraneuronal Aβ peptides in mouse models of Alzheimer's disease
  105. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
  106. Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model
  107. Circulating immune complexes of Aβ and IgM in plasma of patients with Alzheimer’s disease
  108. APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy
  109. Die modifizierte Amyloid-Hypothese der Alzheimer-Demenz – intraneuronales Abeta induziert Neurodegeneration
  110. Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice
  111. Effect of copper intake on CSF parameters in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial
  112. Early Intraneuronal β-Amyloid Pathology: Do Transgenic Mice Represent Valid Model Systems?
  113. Alzheimer-Demenz
  114. Age-dependent loss of dentate gyrus granule cells in APP/PS1KI mice
  115. Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease
  116. Motor impairment in Alzheimer’s disease and transgenic Alzheimer’s disease mouse models
  117. Review on the APP/PS1KI mouse model: intraneuronal Aβ accumulation triggers axonopathy, neuron loss and working memory impairment
  118. Intraneuronal β-Amyloid Is a Major Risk Factor – Novel Evidence from the APP/PS1KI Mouse Model
  119. Age-dependent axonal degeneration in an Alzheimer mouse model
  120. Altered cholesterol metabolism in APP695-transfected neuroblastoma cells
  121. Gender dependent APP processing in a transgenic mouse model of Alzheimer’s disease
  122. Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer’s disease
  123. Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease
  124. OTX1 and OTX2 Expression Correlates With the Clinicopathologic Classification of Medulloblastomas
  125. Traumatic brain injury: cause or risk of Alzheimer’s disease? A review of experimental studies
  126. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide - the first step of a fatal cascade
  127. Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice
  128. No alterations of hippocampal neuronal number and synaptic bouton number in a transgenic mouse model expressing the β-cleaved C-terminal APP fragment
  129. α-Synuclein, Aβ and Alzheimer's disease
  130. Reelin in plaques of β-amyloid precursor protein and presenilin-1 double-transgenic mice
  131. Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice